Browsing Vanderbilt University Medical Center by Subject "vesus-host-disease"
Now showing items 1-1 of 1
-
(FRONTIERS IN ONCOLOGY, 2019-07-10)Dosing regimens for antithymocyte globulin (ATG) and anti-CD52 antibody (alemtuzumab) for graft vs. host disease prophylaxis (GVHD) are empiric or weight-based, and do not account for individual patient factors. Recently, ...